111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
度普利尤单抗在中国特应性皮炎患者中的真实世界评估：疗效、安全性及合并症的影响
Authors Zhang P, Chen H , Huang N, Li W, Yang Y, Ma D , Fu Y, Liu J, Xu Q, Li L, Zhu R
Received 8 October 2025
Accepted for publication 10 December 2025
Published 17 December 2025 Volume 2025:18 Pages 1795—1811
DOI https://doi.org/10.2147/JAA.S567753
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Luis Garcia-Marcos
Panyu Zhang,1 Hao Chen,1 Nan Huang,1 Wenjing Li,1 Yaqi Yang,1 Dongxia Ma,1 Yangxue Fu,1 Jin Liu,1 Qingxiu Xu,1 Le Li,1 Rongfei Zhu1,2
1Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 2Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
Correspondence: Rongfei Zhu, Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei, 430030, People’s Republic of China, Email zrf13092@163.com
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease often accompanied by comorbidities such as allergic rhinitis (AR) and asthma. Dupilumab, a monoclonal antibody targeting IL-4Rα, has demonstrated significant efficacy and safety in the treatment of AD. However, its effectiveness in patients with comorbidities remains underexplored. We aimed to evaluate the impact of Dupilumab on the severity of dermatitis, comorbidity control, medication safety, and treatment adherence in Chinese AD patients in real-world settings.
Methods: This is a single-center retrospective-prospective real-world cohort study that included 376 patients with AD who received Dupilumab treatment from February 2021 to February 2024. Among them, 270 patients had AD, and 106 had AD with comorbidities, including 106 cases of AR and 20 cases of asthma. Baseline clinical data and laboratory parameters were collected. The severity of AD, quality of life, and comorbidity control were assessed at week 0, 4, 8, 12, and 16. Efficacy indicators and related predictive factors were evaluated, and drug continuation rates at week 52 were assessed.
Results: After 16 weeks of Dupilumab treatment, the median improvement in EASI score was 95.3% (from 8.5 to 0.40), with an EASI75 response rate of 78.9%. AD efficacy-related scores and comorbidity-related scores showed significant improvement compared to baseline (all P< 0.05). There was no statistical difference in efficacy between the AD group and AD with comorbidities group. Drug survival analysis showed similar drug continuation rates at 52 weeks for both groups (P> 0.05). Adverse events were mainly eye-related events (8.51%, 32/376), followed by localized symptom worsening (2.13%), hair loss (1.60%), and facial erythema (1.33%). Patients with higher baseline EASI scores were more likely to achieve 90– 100% improvement (P = 0.024).
Conclusion: Dupilumab effectively improves AD symptoms and comorbidities, with consistent efficacy across comorbid status and good safety profile. Higher baseline disease severity associates with better treatment response.
Keywords: atopic dermatitis, Dupilumab, allergic rhinitis, asthma, real-world study
1Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 2Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
Correspondence: Rongfei Zhu, Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei, 430030, People’s Republic of China, Email zrf13092@163.com
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease often accompanied by comorbidities such as allergic rhinitis (AR) and asthma. Dupilumab, a monoclonal antibody targeting IL-4Rα, has demonstrated significant efficacy and safety in the treatment of AD. However, its effectiveness in patients with comorbidities remains underexplored. We aimed to evaluate the impact of Dupilumab on the severity of dermatitis, comorbidity control, medication safety, and treatment adherence in Chinese AD patients in real-world settings.
Methods: This is a single-center retrospective-prospective real-world cohort study that included 376 patients with AD who received Dupilumab treatment from February 2021 to February 2024. Among them, 270 patients had AD, and 106 had AD with comorbidities, including 106 cases of AR and 20 cases of asthma. Baseline clinical data and laboratory parameters were collected. The severity of AD, quality of life, and comorbidity control were assessed at week 0, 4, 8, 12, and 16. Efficacy indicators and related predictive factors were evaluated, and drug continuation rates at week 52 were assessed.
Results: After 16 weeks of Dupilumab treatment, the median improvement in EASI score was 95.3% (from 8.5 to 0.40), with an EASI75 response rate of 78.9%. AD efficacy-related scores and comorbidity-related scores showed significant improvement compared to baseline (all P< 0.05). There was no statistical difference in efficacy between the AD group and AD with comorbidities group. Drug survival analysis showed similar drug continuation rates at 52 weeks for both groups (P> 0.05). Adverse events were mainly eye-related events (8.51%, 32/376), followed by localized symptom worsening (2.13%), hair loss (1.60%), and facial erythema (1.33%). Patients with higher baseline EASI scores were more likely to achieve 90– 100% improvement (P = 0.024).
Conclusion: Dupilumab effectively improves AD symptoms and comorbidities, with consistent efficacy across comorbid status and good safety profile. Higher baseline disease severity associates with better treatment response.
Keywords: atopic dermatitis, Dupilumab, allergic rhinitis, asthma, real-world study